News Center
-
World's First CDK2/4/6 Inhibitor Approved for Marketing, Culmerciclib Capsules (Saitanxin?) Reshape the Breast Cancer Treatment Landscape
On December 11, the world's first CDK2/4/6 inhibitor, Culmerciclib Capsules (Saitanxin?), received a drug registration approval letter from the National Medical Products Administration (NMPA).View -
Sino Biopharm Donates HK$10 Million in Cash and Medicine for Emergency Relief of Tai Po Fire in Hong Kong
On November 26, a sudden fire broke out at Wang Fuk Court in Tai Po District, New Territories, Hong Kong, drawing concern from across the nation.View -
Ms. Theresa Tse Attended Qisi Conference: Inflection Point for Domestic M&A in China's Pharmaceutical Industry Has Arrived, Sino Biopharm Embarks on a New Decade
On November 25, the 17th China Pharmaceutical Entrepreneurs, Scientists and Investors Conference 2025 (hereinafter referred to as the "Qisi Conference") opened in Beijing.View -
.png)
Sino Biopharm Ranks Third on "China's Top 100 Pharmaceutical Innovation Enterprises" List for the Seventh Consecutive Year, Remaining in the First Tier
On October 20, the "2025 China's Top 100 Pharmaceutical Innovation Enterprises" list was released. Sino Biopharm (1177.HK) once again ranks the third. Since the list was first published in 2019, Sino Biopharm has been ranked in the first tier for seven consecutive years, reflecting Sino Biopharm's excellent strategic focus and sustained innovation momentum in a complex and ever-changing industrial environment.View
Science for a healthier world
